Integrated multi-omics demonstrates enhanced antitumor efficacy of donafenib combined with FADS2 inhibition in hepatocellular carcinoma

Integrated multi-omics demonstrates enhanced antitumor efficacy of donafenib combined with FADS2 inhibition in hepatocellular carcinoma

Pharmacotherapy is crucial for advanced hepatocellular carcinoma (HCC). The multi-kinase inhibitor donafenib offers superior survival benefits over sorafenib. Donafenib has first-line status, but there is limited research for combination therapies with this anticancer agent. This study aimed to deli...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Li, Yafeng Dai, Di Wu, Song Gao, Jianhai Guo, Pengjun Zhang, Hui Chen, Fuxin Kou, Shaoxing Liu, Aiwei Feng, Baojiang Liu, Dongdong Hou, Xu Zhu
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Translational Oncology
Subjects:
Hepatocellular carcinoma
Donafenib
Fatty acid desaturase 2
Combination therapy
Multi-omics analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324002699
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1936523324002699

Similar Items